Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
CryoPort, Inc. (CYRX) – Form 144 Filing Overview
An insider, identified in the filing as Ramkumar Mandalam, has filed a Form 144 indicating his intent to sell 13,321 common shares of CryoPort through broker Morgan Stanley Smith Barney on or about 24 June 2025. Based on the stated aggregate market value of $87,385.76, the planned transaction equates to an implied price of roughly $6.56 per share.
The filing also discloses that Mandalam has already disposed of 16,334 shares in four separate transactions between 9 June 2025 and 13 June 2025, generating gross proceeds of $115,000 +. Combining past and proposed sales, total recent dispositions amount to 29,655 shares.
Relative to CryoPort’s 50.14 million shares outstanding, the proposed sale represents approximately 0.03 % of total shares, and the cumulative three-month sales represent about 0.06 %, suggesting limited dilution risk. The shares to be sold were acquired via a same-day stock-option exercise paid in cash. No adverse, non-public information is asserted by the filer, as required under Rule 144.
For investors, Form 144 signals potential insider sentiment changes, but the modest size versus the share count indicates a low direct share-supply impact. Nevertheless, repeated sales within a short window may warrant monitoring for future filings.
Jerrell Shelton, President, CEO, and Director of Cryoport (CYRX), executed significant stock option exercises and sales between June 17-20, 2025, as part of a pre-planned trading arrangement.
Key transactions include:
- Exercised options for 389,720 total shares at $5.00 strike price
- Sold 339,720 shares at weighted average prices between $6.33-$6.97
- Retained 50,000 shares from initial exercise
- Maintained beneficial ownership of 912,419 shares post-transactions
The transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025. The exercised options were originally granted in August 2015 with a 48-month vesting schedule. After all transactions, Shelton continues to hold 166,344 unexercised stock options with an August 2025 expiration date.